Hyperuricemia Treatment Market - Forecasts from 2025 to 2030
Description
The Hyperuricemia Treatment Market is expected to grow at a CAGR of 6.31%, reaching a market size of US$4.329 billion in 2030 from US$3.188 billion in 2025
Hyperuricemia is a condition characterised by elevated levels of serum uric acid in the body, generally greater than 6 mg/dL in women and 7 mg/dL in men. It results from increased uric acid production, decreased excretion or a combination of both factors. This increase in the level of uric acid in the blood leads to disorders like gout, kidney stones, renal disorders, and chronic kidney diseases and is linked to many other related diseases like cardiovascular diseases, diabetes, hypertension, fatty liver disease, Psoriasis and some others. As per the data from the National Center for Biotechnology Information, up to 21% of the general population and 25% of hospitalized patients are estimated to have asymptomatic hyperuricemia.
Market Trends:
Technological Advancements Propel Diagnosis and Treatment
Innovations in hyperuricemia management are accelerating market growth through enhanced diagnostics and therapies. Developments include advanced biomarker identification, genetic testing, and uricosuric drugs that reduce uric acid production. Novel drug delivery systems, such as nanoparticle-based targeted therapies, are also gaining traction. Research into precision treatments, like the combination of pegylated recombinant uricase (pegadricase) and immune tolerance technology for mTOR inhibitors (ImmTOR™), is redefining gout therapy. Ongoing R&D efforts by institutions and universities continue to drive market expansion by offering innovative solutions for hyperuricemia and associated conditions.
Asia Pacific to Experience Rapid Market Growth
The Asia Pacific region is projected to be the fastest-growing hyperuricemia market during the forecast period, driven by increasing prevalence due to sedentary lifestyles, obesity, diabetes, and hypertension. Countries like India (44.6% prevalence) and China (17.7% in 2017, per NHANES) are seeing rising cases. Improved healthcare access and growing awareness further contribute to market growth.
North America Maintains Significant Market Share
North America holds a substantial share of the hyperuricemia market, supported by advanced healthcare infrastructure, an aging population, and sedentary lifestyles. The U.S. National Health and Nutrition Examination Survey estimates 21% of U.S. adults (43 million) and 20.6% of Mexicans have hyperuricemia. The National Institute of Diabetes and Digestive and Kidney Diseases reports that 11% of men and 6% of women experience kidney stones, with chronic kidney disease most prevalent among those aged 65+ (34%). These factors, combined with the aging demographic, drive market growth in the region.
Some of the major players covered in this report include Nippon Chemiphar, Astellas Pharma, AstraZeneca, Tonghua Dongbao Pharmaceutical, Teva Pharmaceutical Industries Ltd., Merck & Co., Sanofi SA, Pfizer Inc., among others.
Key Benefits of this Report:
Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.
What do businesses use our reports for?
Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence
Report Coverage:
Historical data from 2022 to 2024 & forecast data from 2025 to 2030
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)
The Hyperuricemia Treatment Market is analysed into the following segments:
By Type of Disease
Gout
Chronic Kidney Diseases
Others
By Treatment Method
Uricosuric agents
Xanthine Oxidase Inhibitors
Recombinant Uricases
Non-Pharmacological Interventions
Others
By End-User
Hospitals
Clinics
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
Japan
South Korea
Australia
India
Indonesia
Thailand
Others
Hyperuricemia is a condition characterised by elevated levels of serum uric acid in the body, generally greater than 6 mg/dL in women and 7 mg/dL in men. It results from increased uric acid production, decreased excretion or a combination of both factors. This increase in the level of uric acid in the blood leads to disorders like gout, kidney stones, renal disorders, and chronic kidney diseases and is linked to many other related diseases like cardiovascular diseases, diabetes, hypertension, fatty liver disease, Psoriasis and some others. As per the data from the National Center for Biotechnology Information, up to 21% of the general population and 25% of hospitalized patients are estimated to have asymptomatic hyperuricemia.
Market Trends:
Technological Advancements Propel Diagnosis and Treatment
Innovations in hyperuricemia management are accelerating market growth through enhanced diagnostics and therapies. Developments include advanced biomarker identification, genetic testing, and uricosuric drugs that reduce uric acid production. Novel drug delivery systems, such as nanoparticle-based targeted therapies, are also gaining traction. Research into precision treatments, like the combination of pegylated recombinant uricase (pegadricase) and immune tolerance technology for mTOR inhibitors (ImmTOR™), is redefining gout therapy. Ongoing R&D efforts by institutions and universities continue to drive market expansion by offering innovative solutions for hyperuricemia and associated conditions.
Asia Pacific to Experience Rapid Market Growth
The Asia Pacific region is projected to be the fastest-growing hyperuricemia market during the forecast period, driven by increasing prevalence due to sedentary lifestyles, obesity, diabetes, and hypertension. Countries like India (44.6% prevalence) and China (17.7% in 2017, per NHANES) are seeing rising cases. Improved healthcare access and growing awareness further contribute to market growth.
North America Maintains Significant Market Share
North America holds a substantial share of the hyperuricemia market, supported by advanced healthcare infrastructure, an aging population, and sedentary lifestyles. The U.S. National Health and Nutrition Examination Survey estimates 21% of U.S. adults (43 million) and 20.6% of Mexicans have hyperuricemia. The National Institute of Diabetes and Digestive and Kidney Diseases reports that 11% of men and 6% of women experience kidney stones, with chronic kidney disease most prevalent among those aged 65+ (34%). These factors, combined with the aging demographic, drive market growth in the region.
Some of the major players covered in this report include Nippon Chemiphar, Astellas Pharma, AstraZeneca, Tonghua Dongbao Pharmaceutical, Teva Pharmaceutical Industries Ltd., Merck & Co., Sanofi SA, Pfizer Inc., among others.
Key Benefits of this Report:
Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.
What do businesses use our reports for?
Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence
Report Coverage:
Historical data from 2022 to 2024 & forecast data from 2025 to 2030
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)
The Hyperuricemia Treatment Market is analysed into the following segments:
By Type of Disease
Gout
Chronic Kidney Diseases
Others
By Treatment Method
Uricosuric agents
Xanthine Oxidase Inhibitors
Recombinant Uricases
Non-Pharmacological Interventions
Others
By End-User
Hospitals
Clinics
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
Japan
South Korea
Australia
India
Indonesia
Thailand
Others
Table of Contents
149 Pages
- 1. INTRODUCTION
- 1.1. Market Overview
- 1.2. Market Definition
- 1.3. Scope of the Study
- 1.4. Market Segmentation
- 1.5. Currency
- 1.6. Assumptions
- 1.7. Base and Forecast Years Timeline
- 1.8. Key Benefits to the Stakeholder
- 2. RESEARCH METHODOLOGY
- 2.1. Research Design
- 2.2. Research Processes
- 3. EXECUTIVE SUMMARY
- 3.1. Key Findings
- 3.2. CXO Perspective
- 4. MARKET DYNAMICS
- 4.1. Market Drivers
- 4.2. Market Restraints
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
- 4.4. Industry Value Chain Analysis
- 4.5. Analyst View
- 5. HYPERURICEMIA TREATMENT MARKET BY TYPE OF DISEASE
- 5.1. Introduction
- 5.2. Gout
- 5.3. Chronic Kidney Diseases
- 5.4. Others
- 6. HYPERURICEMIA TREATMENT MARKET BY TREATMENT METHOD
- 6.1. Introduction
- 6.2. Uricosuric agents
- 6.3. Xanthine Oxidase Inhibitors
- 6.4. Recombinant Uricases
- 6.5. Non-Pharmacological Interventions
- 6.6. Others
- 7. HYPERURICEMIA TREATMENT MARKET BY END-USER
- 7.1. Introduction
- 7.2. Hospitals
- 7.3. Clinics
- 7.4. Others
- 8. HYPERURICEMIA TREATMENT MARKET BY GEOGRAPHY
- 8.1. Introduction
- 8.2. North America
- 8.2.1. By Type of Disease
- 8.2.2. By Treatment Method
- 8.2.3. By End-User
- 8.2.4. By Country
- 8.2.4.1. USA
- 8.2.4.2. Canada
- 8.2.4.3. Mexico
- 8.3. South America
- 8.3.1. By Type of Disease
- 8.3.2. By Treatment Method
- 8.3.3. By End-User
- 8.3.4. By Country
- 8.3.4.1. Brazil
- 8.3.4.2. Argentina
- 8.3.4.3. Others
- 8.4. Europe
- 8.4.1. By Type of Disease
- 8.4.2. By Treatment Method
- 8.4.3. By End-User
- 8.4.4. By Country
- 8.4.4.1. United Kingdom
- 8.4.4.2. Germany
- 8.4.4.3. France
- 8.4.4.4. Spain
- 8.4.4.5. Others
- 8.5. Middle East and Africa
- 8.5.1. By Type of Disease
- 8.5.2. By Treatment Method
- 8.5.3. By End-User
- 8.5.4. By Country
- 8.5.4.1. Saudi Arabia
- 8.5.4.2. UAE
- 8.5.4.3. Others
- 8.6. Asia Pacific
- 8.6.1. By Type of Disease
- 8.6.2. By Treatment Method
- 8.6.3. By End-User
- 8.6.4. By Country
- 8.6.4.1. China
- 8.6.4.2. Japan
- 8.6.4.3. South Korea
- 8.6.4.4. Australia
- 8.6.4.5. India
- 8.6.4.6. Indonesia
- 8.6.4.7. Thailand
- 8.6.4.8. Others
- 9. COMPETITIVE ENVIRONMENT AND ANALYSIS
- 9.1. Major Players and Strategy Analysis
- 9.2. Market Share Analysis
- 9.3. Mergers, Acquisitions, Agreements, and Collaborations
- 9.4. Competitive Dashboard
- 10. COMPANY PROFILES
- 10.1. Nippon Chemiphar
- 10.2. Astellas Pharma
- 10.3. AstraZeneca
- 10.4. Tonghua Dongbao Pharmaceutical
- 10.5. Teva Pharmaceutical Industries Ltd.
- 10.6. Merck & Co.
- 10.7. Sanofi SA
- 10.8. Pfizer Inc.
- 10.9. Amgen Inc.
- 10.10. Takeda Pharmaceutical Company Limited
- 10.11. Novartis AG
- 10.12. GlaxoSmithKline plc
- 10.13. Kissei Pharmaceutical Co., Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
